Montané Eva, Ibáñez Luisa, Vidal Xavier, Ballarín Elena, Puig Ramon, García Nuria, Laporte Joan-Ramon
Fundació Institut Català de Farmacologia, Barcelona, Spain.
Haematologica. 2008 Apr;93(4):518-23. doi: 10.3324/haematol.12020. Epub 2008 Mar 5.
Aplastic anemia is a rare and severe disease. Its incidence varies considerably worldwide. We aimed at describing the epidemiology of this disease, including the incidence, mortality and survival trends, in a well-defined population.
Since 1980, a case-control surveillance study of aplastic anemia has been carried out by a cooperative group, in the metropolitan area of Barcelona. Inclusion is dependent on the patient having at least two of the following features: white blood cell count < or = 3.5 x 10(9)/L, platelet count < or = 50 x 10(9)/L, hemoglobin <10 g/L or hematocrit of <30%; when only one of these last two criteria is fulfilled, a reticulocyte count of < or = 30 x 10(9)/L is also required. The bone marrow biopsy has to be compatible with the diagnosis of aplastic anemia.
Between 1980 and 2003, a total of 235 cases of aplastic anemia were identified. The overall incidence was 2.34 per million inhabitants per year and the incidence increased with age. Most of the cases were classified as severe or very severe aplastic anemia. Survival rates at 3 months, and at 2 and 15 years after the diagnosis were 73%, 57%, and 51%, respectively. Advanced age and more severe disease at the time of diagnosis were associated with a lower survival rate. There was a trend to a better 2-year survival rate among patients treated with bone marrow transplantation. Forty-nine cases (20.8%) were exposed to drugs reported to be associated with aplastic anemia, and 21 (8.9%) to toxic agents.
The incidence of aplastic anemia in Barcelona is low but the case fatality rate is high. Advanced age and severe disease at the time of diagnosis were associated with decreased survival.
再生障碍性贫血是一种罕见的严重疾病。其发病率在全球范围内差异很大。我们旨在描述这一疾病在一个明确界定的人群中的流行病学情况,包括发病率、死亡率和生存趋势。
自1980年以来,一个合作小组在巴塞罗那大都市区开展了一项再生障碍性贫血的病例对照监测研究。纳入标准取决于患者至少具备以下两项特征:白细胞计数≤3.5×10⁹/L、血小板计数≤50×10⁹/L、血红蛋白<10g/L或血细胞比容<30%;当仅满足最后两项标准中的一项时,还要求网织红细胞计数≤30×10⁹/L。骨髓活检必须与再生障碍性贫血的诊断相符。
1980年至2003年期间,共确诊235例再生障碍性贫血病例。总体发病率为每年每百万居民2.34例,且发病率随年龄增长而增加。大多数病例被归类为重度或极重度再生障碍性贫血。诊断后3个月、2年和15年的生存率分别为73%、57%和51%。诊断时年龄较大和病情较重与较低的生存率相关。接受骨髓移植治疗的患者2年生存率有提高的趋势。49例(20.8%)患者接触过据报道与再生障碍性贫血有关的药物,21例(8.9%)接触过有毒物质。
巴塞罗那再生障碍性贫血的发病率较低,但病死率较高。诊断时年龄较大和病情严重与生存率降低相关。